- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Senate passes Drug Quality and Security Act
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
HAWTHORNE, N.Y. — Taro said that the Food and Drug Administration has declared the drug maker's manufacturing facility in Canada as having acceptable regulatory status.
The drug maker said it diligently worked to resolve issues noted in an FDA warning letter dated Feb. 5, 2009. The regulatory agency reinspected the manufacturing facility last February.
"We are dedicated to developing and manufacturing quality products for our customers while meeting and exceeding all good manufacturing practices standards set by the FDA and Health Canada," said James Kedrowski, interim CEO for Taro.